CIPLA LTD vs NEPHROCARE HEALTH SERV L
A side-by-side comparison of CIPLA LTD (CIPLA) and NEPHROCARE HEALTH SERV L (NEPHROPLUS) — valuation, profitability, growth, and financial health — to help you judge which is the stronger buy today.
On the numbers, CIPLA LTD leads CIPLA vs NEPHROPLUS on 10 of 14 metrics (2 undecided). See the breakdown below — the right pick still depends on your goals (value vs growth, risk appetite).
- Valuation40
- Profitability21
- Growth01
- Size & financial health40
Each axis shows this group's split of that metric, scaled so the leader sits at the edge. Relative to each other, not an absolute score.
Valuation
CIPLA takes 4/4How expensive each stock is relative to its earnings and book value. Lower usually means cheaper.
Profitability
CIPLA takes 2/4How efficiently each company turns capital and sales into profit. Higher is better.
Growth
NEPHROPLUS takes 1/2Three-year compounded growth. Faster-growing businesses can justify a higher valuation.
Size & financial health
CIPLA takes 4/4Scale and balance-sheet strength. Bigger revenue/profit and lower debt are generally safer.
- + ["Company is almost debt free.", "Company has been maintaining a healthy dividend payout of 25.7%"]
- − ["The company has delivered a poor sales growth of 8.01% over past five years.", "Promoter holding has decreased over last 3 years: -4.24%"]
- + ["Company has reduced debt.", "Company is almost debt free.", "Company has delivered good profit growth of 162% CAGR over last 5 years"]
- − ["Stock is trading at 6.22 times its book value", "Though the company is reporting repeated profits, it is not paying out dividend", "Company has a low return on equity of 10.2% over last 3 years.", "Company's cost of borrowing seems high"]
This comparison is for informational purposes only and is not investment advice. Please consult a SEBI-registered advisor before investing.